Video Gallery
Immunovia’s pancreatic cancer awareness campaign between August 12 to September 30, 2019 in Times Square, New York City, highlighting the importance of early detection.
WCVB Channel 5 News covered on the 2nd of May 2019, 5 pm EST Immunovia’s IMMray™ PanCan-d for early detection of pancreatic cancer: “Promising results reported for early detection blood test targeting pancreatic cancer”.
IMMray™ technology:
IMMray™ PanCan–d is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma. Published January 2016.
IMMray™ technology – Short Version:
IMMray™ PanCan–d is the first blood-based test for early and specific (differential) diagnosis, providing clinicians with actionable information. Immunovia has defined a clinically relevant condensed panel of serum biomarkers (a biomarker signature) associated with pancreatic adenocarcinoma. Published November 2015.
